Research Topics
Genomes and Genes | William KaelinSummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
HIF hydroxylation and the mammalian oxygen-sensing pathwayMichal Safran
Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
J Clin Invest 111:779-83. 2003
The concept of synthetic lethality in the context of anticancer therapyWilliam G Kaelin
Howard Hughes Medical Institute, 44 Binney Street, Mayer 457, Boston, Massachusetts 02115, USA
Nat Rev Cancer 5:689-98. 2005..This is changing as a result of the increased availability of chemical and genetic tools for perturbing gene function in somatic cells...
Influence of metabolism on epigenetics and diseaseWilliam G Kaelin
Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
Cell 153:56-69. 2013..Here, we review literature pertinent to hypothetical connections between metabolic and epigenetic states in eukaryotic cells...
Treatment of erythropoietin deficiency in mice with systemically administered siRNAWilliam Querbes
Alnylam Pharmaceuticals, Cambridge, MA 02215, USA
Blood 120:1916-22. 2012....
Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenasesW G Kaelin
Howard Hughes Medical Institute, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
Cold Spring Harb Symp Quant Biol 76:335-45. 2011..2-Oxoglutarate-dependent dioxygenases therefore provide a link between altered metabolism and cancer...
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathwayWilliam G Kaelin
Howard Hughes Medical Institute, Boston, MA 02115, USA
Mol Cell 30:393-402. 2008..HIF affects signaling pathways that influence development, metabolism, inflammation, and integrative physiology. Accordingly, HIF-modulatory drugs are now being developed for diverse diseases...
Von Hippel-Lindau diseaseWilliam G Kaelin
Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Annu Rev Pathol 2:145-73. 2007..It is hypothesized that tumor-associated alleles of these genes allow primitive sympathoadrenal precursors to escape developmental culling, and that such cells are at increased risk of forming tumors...
The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinomaWilliam G Kaelin
Howard Hughes Medical Institute, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Clin Cancer Res 13:680s-684s. 2007....
The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensingWilliam G Kaelin
Howard Hughes Medical Institute, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Biochem Biophys Res Commun 338:627-38. 2005..Pharmacological manipulation of HIF activity might be beneficial in diseases characterized by abnormal tissue oxygenation including myocardial infarction, cerebrovascular disease, and cancer...
Alterations in G1/S cell-cycle control contributing to carcinogenesisW G Kaelin
Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Ann N Y Acad Sci 833:29-33. 1997..Thus, E2F appears to be a physiologically relevant target of pRB action, and deregulation of E2F-responsive genes is a common, and possibly universal, step in human carcinogenesis...
E2F1 as a target: promoter-driven suicide and small molecule modulatorsWilliam G Kaelin
Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
Cancer Biol Ther 2:S48-54. 2003..This chapter will review the role of E2F in cancer and outline opportunities for the development of anticancer agents based on E2F biology...
The von Hippel-Lindau gene, kidney cancer, and oxygen sensingWilliam G Kaelin
Howard Hughes Medical Institute, Dana Farber Cancer Institute, and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Am Soc Nephrol 14:2703-11. 2003..This review summarizes the current knowledge of the molecular pathogenesis of von Hippel-Lindau disease and the role of the VHL gene product (pVHL) in kidney cancer and the mammalian oxygen sensing pathway...
Proline hydroxylation and gene expressionWilliam G Kaelin
Howard Hughes Medical Institute, Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA
Annu Rev Biochem 74:115-28. 2005..The existence of three human EGLN family members, as well as other putative hydroxylases, raises the possibility that this signal is used in other contexts by other proteins...
The von Hippel-Lindau tumor suppressor gene and kidney cancerWilliam G Kaelin
Howard Hughes Medical Institute, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Clin Cancer Res 10:6290S-5S. 2004..Genotype-phenotype correlations in VHL disease suggest, however, that pVHL has targets in addition to HIF. Elucidating these targets should provide a more complete picture of how pVHL suppresses tumor growth...
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancerWilliam G Kaelin
Howard Hughes Medical Institute, Chevy Chase, Maryland 20815 6789, USA
Nat Rev Cancer 8:865-73. 2008....
Molecular basis of the VHL hereditary cancer syndromeWilliam G Kaelin
Howard Hughes Medical Institute, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Nat Rev Cancer 2:673-82. 2002..These studies, in turn, are laying the foundation for the treatment of a diverse set of disorders, including cancer, myocardial infarction and stroke...
Functions of the von Hippel-Lindau tumour suppressor proteinW G Kaelin
Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
J Intern Med 243:535-9. 1998..In this regard, it is perhaps noteworthy that elongin C and Cul2 are homologous to yeast proteins Skp1 and Cdc53. These latter proteins participate in the formation of complexes that target certain proteins for ubiquitination...
The emerging p53 gene familyW G Kaelin
Howard Hughes Medical Institute and Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
J Natl Cancer Inst 91:594-8. 1999..Additional studies are required to determine the role, if any, that p73 and p51 play in cell growth control and carcinogenesis...
Functions of the retinoblastoma proteinW G Kaelin
Department of Adult Oncology and Howard Hughes Medical Institute, Dana Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts, USA
Bioessays 21:950-8. 1999..The untimely activation of E2F responsive genes can induce apoptosis. This comes about at least partly through the induction of ARF, which leads to the stabilization and activation of p53. BioEssays 1999;21:950-958...
The p53 gene familyW G Kaelin
Howard Hughes Medical Institute and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA 02115, USA
Oncogene 18:7701-5. 1999....
New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor proteinWilliam G Kaelin
Howard Hughes Medical Institute, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Ann N Y Acad Sci 1210:1-7. 2010..A number of JmjC-containing proteins, including RBP2 and PLU-1, are 2-oxoglutarate-dependent dioxygenases that demethylate histones. Preclinical data suggest that inhibition of RBP2 or PLU-1 would suppress tumor growth...
Synthetic lethality: a framework for the development of wiser cancer therapeuticsWilliam G Kaelin
Howard Hughes Medical Institute, Dana Farber Cancer Institute and Brigham and Women s Hospital, 44 Binney St, Boston, MA 02115, USA
Genome Med 1:99. 2009..These approaches will hopefully facilitate the discovery of safer, more efficacious anticancer drugs that exploit vulnerabilities that are unique to cancer cells by virtue of the mutations they have accrued during tumor progression...
How oxygen makes its presence feltWilliam G Kaelin
Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Genes Dev 16:1441-5. 2002
SDH5 mutations and familial paraganglioma: somewhere Warburg is smilingWilliam G Kaelin
Howard Hughes Medical Institute, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
Cancer Cell 16:180-2. 2009..Moreover, they detected SDH5 mutations in a large kindred with familial paraganglioma...
Treatment of kidney cancer: insights provided by the VHL tumor-suppressor proteinWilliam G Kaelin
Howard Hughes Medical Institute, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Mayer 457, Boston, MA 02115, USA
Cancer 115:2262-72. 2009..Loss of the primary cilium probably facilitates the development of preneoplastic renal cysts, whereas increased NFkappaB might contribute to the resistance of kidney cancers to conventional cytotoxic agents...
Kidney cancer: now available in a new flavorWilliam G Kaelin
Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 14:423-4. 2008..In this issue, Simon and coworkers show that the molecular signature of VHL(-/-) kidney cancers is profoundly influenced by whether they produce both HIF2alpha and HIF1alpha or HIF2alpha alone...
Role of VHL gene mutation in human cancerWilliam Y Kim
Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
J Clin Oncol 22:4991-5004. 2004..On the other hand, clear genotype-phenotype correlations are emerging in VHL disease and can be rationalized if pVHL has functions separate from its control of HIF...
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancerWilliam Kim
Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
Curr Opin Genet Dev 13:55-60. 2003....
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancerSungwoo Lee
Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Cell 8:155-67. 2005..Moreover, EglN3 proapoptotic activity requires SDH activity because EglN3 is feedback inhibited by succinate. These studies suggest that failure of developmental apoptosis plays a role in pheochromocytoma pathogenesis...
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factorMircea Ivan
Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 99:13459-64. 2002..A model compound of this series stabilized HIF in a variety of cells, leading to the increased production of its downstream target, vascular endothelial growth factor...
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau proteinKeiichi Kondo
Department of Adult Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 1:237-46. 2002..These studies prove that HIF is a critical downstream target of pVHL and establish that activation of HIF target genes can promote tumorigenesis in vivo...
VHL and kidney cancerMichael Ohh
Dana-Farber Cancer Institute, Boston, MA, USA
Methods Mol Biol 222:167-83. 2003
TSC2 regulates VEGF through mTOR-dependent and -independent pathwaysJames B Brugarolas
Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Cancer Cell 4:147-58. 2003..This pathway may involve chromatin remodeling since the HDAC inhibitor Trichostatin A downregulates VEGF in TSC2(-/-) cells...
The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancerDaniel J George
Dana-Farber Cancer Institute, Boston, USA
N Engl J Med 349:419-21. 2003
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growthKeiichi Kondo
Department of Adult Oncology, Dana Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, USA
PLoS Biol 1:E83. 2003..These results establish that tumor suppression by pVHL is linked to regulation of HIF target genes...
Senescence triggered by the loss of the VHL tumor suppressorArthur P Young
Department of Developmental and Stem Cell Biology, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Cell Cycle 7:1709-12. 2008
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidneyRameen Beroukhim
Departments of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA
Cancer Res 69:4674-81. 2009....
ROS: really involved in oxygen sensingWilliam G Kaelin
Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Cell Metab 1:357-8. 2005..2005) used genetic tools to establish that ROS produced by mitochondria are required for the normal induction of HIF (hypoxia-inducible factor), which is a master regulator of oxygen-sensitive gene expression, by low oxygen...
Innovations and challenges in renal cancer: summary statement from the Third Cambridge ConferenceMichael B Atkins
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Cancer 115:2247-51. 2009..The conference format combined brief presentations with extended periods of discussion. The conclusions and recommendations are summarized in this paper and presented in more detail in the individual papers that follow...
Chemosensitivity linked to p73 functionMeredith S Irwin
Dana-Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 3:403-10. 2003..Mutant p53 can inactivate p73 and downregulation of mutant p53 enhanced chemosensitivity. These findings indicate that p73 is a determinant of chemotherapeutic efficacy in humans...
Prostate cancer: beta control your hormonesMassimo Loda
Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 17:311-2. 2010....
Analysis of von Hippel-Lindau hereditary cancer syndrome: implications of oxygen sensingHaifeng Yang
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Methods Enzymol 381:320-35. 2004
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressorSusanne Schlisio
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Genes Dev 22:884-93. 2008....
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge ConferenceMichael B Atkins
Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
Clin Cancer Res 13:667s-670s. 2007....
Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor proteinEijiro Nakamura
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Am J Pathol 168:574-84. 2006..Therefore, clusterin is a secreted marker for a HIF-independent pVHL function that might be especially important in pheochromocytoma development...
Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutationsLianjie Li
Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Mayer 457, Boston, MA 02115, USA
Mol Cell Biol 27:5381-92. 2007..Therefore, quantitative differences with respect to HIF deregulation are sufficient to account for the differential risks of kidney cancer linked to VHL mutations...
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complexJames Brugarolas
Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Genes Dev 18:2893-904. 2004..Inhibition of mTOR function by hypoxia is likely to be important for tumor suppression as TSC2-deficient cells maintain abnormally high levels of cell proliferation under hypoxia...
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesisBoyi Gan
Belfer Institute for Applied Cancer Science, Boston, MA 02115, USA
Cancer Cell 18:472-84. 2010....
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400Arthur P Young
Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Nat Cell Biol 10:361-9. 2008..Our results suggest that senescence induced by VHL inactivation is a tumour-suppressive mechanism that must be overcome to develop VHL-associated neoplasias...
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromesJames Brugarolas
Dana-Farber Cancer Institute and Harvard Medical School, Howard Hughes Medical Institute, 44 Binney Street, Mayer 457, Boston, Massachusetts 02115, USA
Cancer Cell 6:7-10. 2004..How mTOR dysregulation after inactivation of LKB1 or TSC1/2 contributes to hamartoma development is not known. However, hypoxia-inducible factor (HIF) and VEGF are regulated by mTOR and are likely to play a contributory role...
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failureYoji Andrew Minamishima
Department of Medical Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Blood 111:3236-44. 2008..The latter is likely the result of hyperviscosity syndrome and volume overload, although a direct effect of chronic, high-level HIF stimulation on cardiac myocytes cannot be excluded...
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylaseQing Zhang
Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 16:413-24. 2009..EglN2 depletion also impairs the fitness of lung, brain, and hematopoietic cancer lines. These findings support the exploration of EglN2 inhibitors as therapeutics for estrogen-dependent breast cancer and other malignancies...
pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2Haifeng Yang
Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Mol Cell 28:15-27. 2007..Therefore pVHL can serve as an adaptor for both a ubiquitin conjugating enzyme and a kinase. The latter activity, which promotes Card9 phosphorylation, links pVHL to control of NF-kappaB activity and tumorigenesis...
An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cellsMichael Ohh
Department of Adult Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
EMBO Rep 3:177-82. 2002..Thus, neddylation regulates the activity of two specific subclasses of mammalian ubiquitin ligases...
Using cancer genetics to guide the selection of anticancer drug targetsArchana Reddy
Howard Hughes Medical Institute, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Curr Opin Pharmacol 2:366-73. 2002....
The retinoblastoma binding protein RBP2 is an H3K4 demethylaseRobert J Klose
Howard Hughes Medical Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Cell 128:889-900. 2007..These studies provide mechanistic insights into transcriptional regulation by RBP2 and provide the first example of a mammalian enzyme capable of erasing trimethylated H3K4...
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligaseWenyi Wei
Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 8:25-33. 2005..These findings explain the enhanced stability and oncogenicity of v-Jun relative to its cellular counterpart and reveal that GSK3 and Fbw7 coordinately regulate c-Jun and c-Myc...
Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivoWilliam Y Kim
Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
EMBO J 25:4650-62. 2006..Therefore, the pathological changes caused by pVHL inactivation in skin and liver are due largely to dysregulation of HIF target genes...
Bioluminescent imaging of Cdk2 inhibition in vivoGuo-Jun Zhang
Department of Adult Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Nat Med 10:643-8. 2004..In theory, the approach described here could be used to develop bioluminescent reporters for any drug target that directly or indirectly affects the turnover of a ubiquitin ligase substrate...
Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathyJavid Moslehi
Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA
Circulation 122:1004-16. 2010....
A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivoYoji Andrew Minamishima
Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Mol Cell Biol 29:5729-41. 2009....
Reactivation of hepatic EPO synthesis in mice after PHD lossYoji Andrew Minamishima
Howard Hughes Medical Institute, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
Science 329:407. 2010....
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin productionMichal Safran
Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 103:105-10. 2006....
Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416Lloyd Paul Aiello
Beetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, Massachusetts 02115, USA
Ophthalmology 109:1745-51. 2002..These findings suggest that continued evaluation of VEGF inhibitors for ocular neovascular disorders is warranted...
Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical investigation in cancerWilliam G Kaelin
Dana Farber Cancer Institute, Boston, Massachusetts, USA
Cancer Res 67:11102-5. 2007..A session was devoted to the identification of markers of drug effectiveness. Two sessions were focused on opportunities for developing new specific molecular target-oriented therapies...
The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivoQin Yan
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Mol Cell Biol 27:2092-102. 2007....
Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exitUlrich K Binné
Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts, MA 02129, USA
Nat Cell Biol 9:225-32. 2007..The results reveal an unexpected physical convergence between the pRB tumour-suppressor protein and E3 ligase complexes, and raise the possibility that pRB may direct APC/C to additional targets during pRB-mediated cell-cycle exit...
Innovations and challenges in renal cancer: consensus statement from the first international conferenceMichael B Atkins
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Clin Cancer Res 10:6277S-81S. 2004
The human p73 promoter: characterization and identification of functional E2F binding sitesRatnam S Seelan
Department of Laboratory Medicine and Pathology, Division of Experimental Pathology, Mayo Clinic and Mayo Medical School, 200 First Street SW, Rochester, MN 55905, USA
Neoplasia 4:195-203. 2002..Two of the three functional E2F sites (at -155 and -132) reside within this region. Our results suggest that regulation of p73 expression is primarily mediated through binding of E2F1 to target sites at -155 and -132...
Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signalingJung Hyun Min
Cellular Biochemistry and Biophysics Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Science 296:1886-9. 2002..Although the beta sheet-like interactions contribute to the stability of the complex, the hydroxyproline contacts are central to the strict specificity characteristic of signaling...
pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor developmentNatalie H Stickle
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada
Mol Cell Biol 24:3251-61. 2004..These results suggest that NEDD8 modification of pVHL plays an important role in fibronectin matrix assembly and that in the absence of such regulation, an intact HIF pathway is insufficient to prevent VHL-associated tumorigenesis...
Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activityWilliam J Hansen
Surgical Research Laboratory, San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94110, USA
Mol Cell Biol 22:1947-60. 2002....
Molecular pathways in renal cell carcinoma--rationale for targeted treatmentWilliam Y Kim
Department of Hematology Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Semin Oncol 33:588-95. 2006..How these agents should be combined with one another and with conventional agents is the subject of current trials...
Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathwaysYide Jiang
Genzyme Molecular Oncology, Framingham, MA 01701, USA
Mol Cancer Res 1:453-62. 2003....
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonistBogdan Z Olenyuk
Division of Chemistry and Chemical Engineering, Beckman Institute, California Institute of Technology, Pasadena, CA 91125, USA
Proc Natl Acad Sci U S A 101:16768-73. 2004..Pathway-based regulation of hypoxia-inducible gene expression with DNA-binding small molecules may represent a new approach for targeting angiogenesis...
Cell biology: divining cancer cell weaknessesWilliam G Kaelin
Nature 441:32-4. 2006
The von hippel-lindau tumor suppressor protein: an updateWilliam G Kaelin
Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, USA
Methods Enzymol 435:371-83. 2007..In addition, recent work suggests that pVHL regulates neuronal apoptosis in an HIF-independent manner, and this activity is linked to the risk of developing pheochromocytoma...
Binding of pRB to the PHD protein RBP2 promotes cellular differentiationElizaveta V Benevolenskaya
Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Mol Cell 18:623-35. 2005..Our results suggest that promotion of differentiation by pRB involves neutralization of free RBP2 and transcriptional activation of RBP2 targets linked to euchromatin maintenance...
Recent insights into the molecular pathogenesis of pheochromocytoma and paragangliomaEijiro Nakamura
Department of Urology, Graduate School of Medicine, Kyoto University
Endocr Pathol 17:97-106. 2006..This review focuses on the genetics of these tumors and suggests a possible link between familial pheochromocytomas/paraganglioma genes and control of neuronal apoptosis during embryological development...
Gleevec: prototype or outlier?William G Kaelin
Howard Hughes Medical Institute, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
Sci STKE 2004:pe12. 2004..Encouraging in this regard are cell culture experiments and animal models that suggest that cancer cells often remain dependent on, and may become addicted to, the signals resulting from such early genetic changes...
Detection of peptides, proteins, and drugs that selectively interact with protein targetsIlya G Serebriiskii
Division of Basic Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Genome Res 12:1785-91. 2002....
Bioluminescent imaging of ubiquitin ligase activity: measuring Cdk2 activity in vivo through changes in p27 turnoverGuo-Jun Zhang
Howard Hughes Medical Institute, Dana-Farber Cancer Institute and Brighan and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
Methods Enzymol 399:530-49. 2005..These approaches should be generalizable to other ubiquitin-ligase substrate pairs...
Research Grants
- Real-Time Imaging of Hypoxia based on VHL ActivityWilliam Kaelin; Fiscal Year: 2006..Such mice could be used to study diseases characterized by the presence of hypoxic cells, such as cancer, and could also be used to monitor pharmacodynamic effects of agents that alter tissue oxygenation and/or modulate HIF. ..
- 2006 Cancer Model MechanismsWilliam Kaelin; Fiscal Year: 2006....
- A Luciferase Fusion Protein Library to Identify & Monitor Ubiquitylation TargetsWilliam Kaelin; Fiscal Year: 2007..Reisolation of HIF in aims 2 and 3 would constitute proof of concept with respect to the potential utility of this approach. ..
- SIGNAL TRANSDUCTION BY THE RETINOBLASTOMA PROTEINWilliam Kaelin; Fiscal Year: 2007..The functional significance of pRB/RBP2 interactions will be addressed in Specific aim 3 and specific aim 4 will ask whether EID1 and/or RBP2 contribute to the developmental abnormalities observed in RB-/- mice. ..
- Functional Analysis of the Von Hippel-Lindau ProteinWilliam Kaelin; Fiscal Year: 2007..This, in turn, is leading to new drugs that might be useful in diseases such as heart attack and stroke that are characterized by impaired oxygen delivery to tissues. ..
- Functional Analysis of the Von Hippel-Lindau ProteinWilliam Kaelin; Fiscal Year: 2009..This, in turn, is leading to new drugs that might be useful in diseases such as heart attack and stroke that are characterized by impaired oxygen delivery to tissues. ..
- Functional Analysis of the Von Hippel-Lindau ProteinWilliam G Kaelin; Fiscal Year: 2010..This, in turn, is leading to new drugs that might be useful in diseases such as heart attack and stroke that are characterized by impaired oxygen delivery to tissues. ..
- Functional Analysis of the von Hippel Lindau ProteinWilliam Kaelin; Fiscal Year: 2005..Identification of additional proteins that bind to, and are regulated by, pVHL is the goal of specific aim 4. ..
- Using Synthetic Lethality to Select Cancer Drug TargetsWilliam Kaelin; Fiscal Year: 2005..Moreover, they may establish a new paradigm for the selection of anticancer drug targets based on inactivating mutations of TSG. ..
- FUNCTIONAL ANALYSIS OF THE VON HIPPEL/LINDAU PROTEINWilliam Kaelin; Fiscal Year: 2000..Furthermore, these cDNAs will likely be invaluable reagents for further exploring the functional significance of pVHL binding to these two proteins. ..
- SIGNAL TRANSDUCTION BY THE RETINOBLASTOMA PROTEINWilliam Kaelin; Fiscal Year: 2002..Testing this hypothesis in a mouse model, as well as determining the biochemical basis for this activity, will form the basis of specific aim 2. ..
- Functional Analysis of the Von Hippel-Lindau ProteinWilliam Kaelin; Fiscal Year: 2009..This, in turn, is leading to new drugs that might be useful in diseases such as heart attack and stroke that are characterized by impaired oxygen delivery to tissues. ..
